Sökning: "bcl-2"
Visar resultat 21 - 25 av 137 avhandlingar innehållade ordet bcl-2.
21. The impact of Bcl-2 family members on mast cell survival and apoptosis
Sammanfattning : Mast cells are long-lived effector cells of the immune system perhaps best known for their involvement in allergic diseases. There are several acute and chronic inflammations where mast cell accumulation, activation and release of mediators are important for the initiation and perpetuation of the inflammation. LÄS MER
22. Involvement of Eicosanoid Signaling in Intestinal Epithelial Cell Survival
Sammanfattning : Eicosanoids are known to be involved in many different aspects of eukaryotic physiology and pathology. Notably, over the past 10 years much attention has been given to cyclooxygenase-2 (COX-2) due to its involvement in colorectal cancer. Less is known about the other major branch of arachidonic acid metabolism, namely the lipoxygenases (LO). LÄS MER
23. Experimental studies on multidrug resistance in human leukaemia : role of cellular heterogeneity for daunorubicin kinetics
Sammanfattning : Cellular resistance to chemotherapy is a major cause of treatment failure in acute myeloid leukaemia (AML) and still the majority of the patients die from their disease. Drug resistance 1s multifactorial, the most studied mechanism being multidrug resistance (MDR), mediated by the P-glycoprotein (Pgp). LÄS MER
24. The role of the mitochondrial membrane system in apoptosis : the influence of oxidative stress on membranes and their interactions with apoptosis-regulating Bcl-2 proteins
Sammanfattning : Apoptosis is a crucial process in multicellular organisms in sculpting them, especially during embryogenesis. In addition, apoptosis is responsible for the clearance of harmful or damaged cells which can otherwise be detrimental to the organism. LÄS MER
25. CD19-targeting CAR T Cells for Treatment of B Cell Malignancies : From Bench to Bedside
Sammanfattning : Immunotherapy for cancer is a young research field progressing at high speed. The first chimera of an antibody and a signaling chain was designed by Zelig Eshhar and was later further developed to enhance existing T cell therapy by combining a single-chain fragment of an antibody with the CD3 zeta chain of the TCR complex. LÄS MER